Bristol-Myers Squibb (BMY) said Friday it received European Commission approval for the perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo to treat resectable non-small cell lung cancer.

The approval covers treatment of cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression greater than or equal to 1%, the company said.